Evidence map›Paper›PMID 29344369›Full record

ArticleOpen heart

Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies.

Michael G Fradley, Federico Viganego, Kevin Kip, Angel Martin, Aarti A Patel, Roohi Ismail-Khan, Sanders Chae, Bengt Herweg, Arthur Labovitz

Open access · goldAbstract read
In one paragraph

Article in Open heart. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond.Journal of cardiovascular translational research · 2020
    Review
  10. Article
  11. Electrophysiologic Toxicity of Chemoradiation.Current oncology reports · 2018
    Review
  12. Electrophysiologic Complications in Cancer Patients.Methodist DeBakey cardiovascular journal
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Michael G FradleyDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.ORCID 0000-0001-8352-8975
Federico ViganegoDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.
Kevin KipDepartment of Epidemiology and Biostatistics, University of South Florida College of Public Health, Tampa, Florida, USA.
Angel MartinDepartment of Internal Medicine, USF Health Morsani College of Medicine, Tampa, Florida, USA.
Aarti A PatelDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.
Roohi Ismail-KhanCardio-Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Sanders ChaeDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.
Bengt HerwegDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.
Arthur LabovitzDivision of Cardiovascular Medicine, University of South Florida, Tampa, Florida, USA.
University of South Florida · USMoffitt Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: There is little information about arrhythmia burden in cancer survivors with chemotherapy-induced cardiomyopathy (CIC). We hypothesise that the rates and risk of arrhythmias will be similar in CIC when compared with other non-ischaemic cardiomyopathy (NICMO) aetiologies. Methods: We retrospectively identified nine patients with CIC and an implantable defibrillator and 18 age and sex-matched control patients (nine patients with NICMO and nine patients with ischaemic cardiomyopathy (ICMO)). Rates and odds of arrhythmias were calculated by type of cardiomyopathy, adjusting for days since implantable cardioverter defibrillator implantation, history of atrial fibrillation and length of follow-up using logistic regression analysis. Results: Compared with patients with NICMO, rates and adjusted odds were similar for patients with CIC for atrial arrhythmias (44.4% vs 33.3%; adjusted OR=1.89; 95% CI0.17 to 21.03; P=0.61), non-sustained ventricular tachycardia (NSVT) (44.4% vs 33.3%; OR=2.10; 95% CI 0.21 to 20.56; P=0.53), and the combined outcome of NSVT, sustained ventricular tachycardia and/or ventricular fibrillation (44.4% vs 44.4%; OR=2.70; 95% CI 0.25 to 29.48; P=0.42). Conversely, compared with patients with NICMO, patients with ICMO demonstrated higher rates and adjusted odds of the combined outcome (88.9% vs 44.4%; OR=28.60; 95% CI 1.26 to 648.2; P=0.04) and NSVT (77.8% vs 33.3%; OR=8.95; 95% CI 0.90 to 88.94; P=0.06). Conclusions: While tentative based on sample size, rates of arrhythmias in patients with CIC appear to be similar to those experienced by patients with other forms of NICMO.

Indexed as

arrhythmiascardio-oncologycardiotoxicitychemotherapy-induced cardiomyopathy

Identifiers

PMID29344369
PMCPMC5761288
OpenAlexW2776056153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.